Ovid therapeutics inc. (OVID)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16
Assets
Current assets:
Cash and cash equivalents

27,336

41,897

37,907

47,361

54,600

36,489

30,513

22,535

29,202

87,125

96,042

106,115

44,225

51,939

Short-term investments

30,996

34,841

-

-

5,040

5,011

21,994

40,059

44,955

-

-

-

-

-

Related party receivable

374

1,131

-

1,594

1,257

600

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

2,029

1,942

1,242

4,650

1,925

2,167

2,746

2,594

1,529

1,462

827

1,195

389

221

Due from related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

7

Deferred transaction costs

-

-

-

-

-

-

-

-

-

-

-

-

1,926

242

Total current assets

60,737

79,813

39,150

53,607

62,823

44,268

55,254

65,189

75,688

88,588

96,870

107,311

46,541

52,411

Long-term prepaid expenses

286

359

1,006

857

3,311

2,797

4,543

2,919

2,638

604

-

-

-

-

Security deposit

153

135

113

113

123

122

121

121

128

88

437

430

415

407

Property and equipment, net

109

68

72

58

66

69

68

67

52

51

51

49

46

43

Other assets

436

467

351

270

331

391

406

313

160

124

207

215

200

165

Total assets

61,723

80,843

40,694

54,908

66,655

47,649

60,393

68,612

78,667

89,457

97,567

108,007

47,203

53,027

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable

3,992

3,256

5,341

2,048

4,410

3,755

4,593

3,429

2,396

2,025

1,456

3,571

1,579

857

Accrued expenses

5,988

7,266

4,681

7,135

3,661

5,088

5,829

4,066

4,182

3,995

3,151

3,493

3,287

2,876

Related party payable

10

10

337

-

-

-

-

-

-

-

-

-

-

-

Total current liabilities

9,991

10,533

10,361

9,183

8,071

8,844

10,422

7,496

6,579

6,021

4,608

7,065

4,867

3,733

Related party payable - noncurrent

286

286

286

286

1,338

-

-

-

-

-

-

-

-

-

Total liabilities

10,278

10,820

10,647

9,470

9,409

8,844

-

-

-

-

-

-

-

-

Stockholders' equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 7,762 shares issued and outstanding at March 31, 2020 and December 31, 2019

0

0

0

0

0

-

0

0

0

-

-

-

-

-

Common stock, $0.001 par value; 125,000,000 shares authorized; 54,754,065 and 54,710,322 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

54

54

37

38

38

24

24

24

24

24

24

24

9

9

Additional paid-in-capital

284,510

283,122

226,196

224,951

223,701

191,477

189,746

187,940

185,997

184,127

-

-

-

-

Accumulated other comprehensive gain

65

2

-

-

1

-1

-4

-16

-35

-

-

-

-

-

Additional paid-in-capital

-

-

-

-

-

-

-

-

-

-

182,689

181,314

112,464

85,186

Accumulated deficit

-233,186

-213,156

-196,187

-179,552

-166,495

-152,695

-139,795

-126,833

-113,898

-100,715

-89,755

-80,396

-70,148

-35,909

Total stockholders' equity

51,444

70,023

30,046

45,437

57,245

38,805

49,971

61,115

72,088

83,436

92,959

100,942

42,335

49,294

Total liabilities and stockholders' equity

61,723

80,843

40,694

54,908

66,655

47,649

60,393

68,612

78,667

89,457

97,567

108,007

47,203

53,027